New drug trial aims to halt Early-Stage blood cancer
NCT ID NCT05055063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with a high-risk form of smoldering multiple myeloma, an early stage of blood cancer. The purpose is to test a drug called belantamab mafodotin to find the safest dose and see if it can control the disease. About 30 participants will receive the drug, and researchers will monitor side effects and how well the cancer responds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged antibody head off a bone marrow cancer before it starts?
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- New dashboard aims to make leukemia trials more inclusive
- Could a new immunotherapy stop smoldering myeloma before it becomes active cancer?
- Four-Drug cocktail aims to halt smoldering myeloma before it strikes
- Gentle touch may soothe anxiety for isolated blood cancer patients